0000950170-24-022413.txt : 20240228 0000950170-24-022413.hdr.sgml : 20240228 20240228182238 ACCESSION NUMBER: 0000950170-24-022413 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240226 FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cohen Joshua B CENTRAL INDEX KEY: 0001898644 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 24697778 MAIL ADDRESS: STREET 1: C/O AMYLYX PHARMACEUTICALS, INC. STREET 2: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 ownership.xml 4 X0508 4 2024-02-26 0001658551 Amylyx Pharmaceuticals, Inc. AMLX 0001898644 Cohen Joshua B C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET CAMBRIDGE MA 02141 true true false false Co-Chief Executive Officer false Common Stock 2024-02-26 4 A false 126667 0.00 A 3027137 D Stock Option (right to buy) 17.56 2024-02-26 4 A false 190000 0.00 A 2034-02-25 Common Stock 190000 190000 D The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. /s/ Joshua B. Cohen 2024-02-28